These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8154521)

  • 41. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group.
    Am J Cardiol; 1993 Apr; 71(10):810-5. PubMed ID: 8456759
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acute myopathy in a patient with concomitant use of pravastatin and colchicine.
    Alayli G; Cengiz K; Cantürk F; Durmuş D; Akyol Y; Menekşe EB
    Ann Pharmacother; 2005; 39(7-8):1358-61. PubMed ID: 15914514
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Hypothyroidism, pravastatin therapy and myopathy].
    Porela P; Kantola I
    Duodecim; 2002; 118(7):689-90. PubMed ID: 12238178
    [No Abstract]   [Full Text] [Related]  

  • 44. HMG-CoA reductase inhibitor therapy and peripheral neuropathy.
    Jacobs MB
    Ann Intern Med; 1994 Jun; 120(11):970. PubMed ID: 8172444
    [No Abstract]   [Full Text] [Related]  

  • 45. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance.
    Kyrklund C; Backman JT; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2003 Jun; 73(6):538-44. PubMed ID: 12811363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.
    Norman DJ; Illingworth DR; Munson J; Hosenpud J
    N Engl J Med; 1988 Jan; 318(1):46-7. PubMed ID: 3275891
    [No Abstract]   [Full Text] [Related]  

  • 47. Relative safety and efficacy of pravastatin.
    Tobert JA
    Clin Pharm; 1993 Apr; 12(4):256-7. PubMed ID: 8458177
    [No Abstract]   [Full Text] [Related]  

  • 48. Simvastatin-induced myopathy in a patient treated for hypercholesterolemia. Morphological aspects.
    Wicher-Muniak E; Zmudka K; Dabroś W; Dudek D; Stachura J
    Pol J Pathol; 1997; 48(1):69-74. PubMed ID: 9200964
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia.
    Partinen M; Pihl S; Strandberg T; Vanhanen H; Murtomäki E; Block G; Neafus R; Haigh J; Miettinen T; Reines S
    Am J Cardiol; 1994 May; 73(12):876-80. PubMed ID: 8184812
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.
    McPherson R; Bedard J; Connelly P; Curnew G; Davignon J; Echenberg D; Lavin P; Leiter L; Lenis J; McQueen M
    Clin Ther; 1992; 14(2):276-91. PubMed ID: 1611649
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A comparison between lovastatin and pravastatin--effects on lipids, sleep and quality of life in primary hyperlipidemia].
    Tonstad S; Gørbitz C; Ose L; Malt UF
    Tidsskr Nor Laegeforen; 1994 Aug; 114(19):2262-4. PubMed ID: 7992293
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
    Murdock DK; Murdock AK; Murdock RW; Olson KJ; Frane AM; Kersten ME; Joyce DM; Gantner SE
    Am Heart J; 1999 Jul; 138(1 Pt 1):151-5. PubMed ID: 10385779
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of therapeutic interchange from pravastatin to lovastatin in a Veterans Affairs Medical Center.
    Patel RJ; Gray DR; Pierce R; Jafari M
    Am J Manag Care; 1999 Apr; 5(4):465-74. PubMed ID: 10387386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Statin-induced myopathy in a patient with previous poliomyelitis.
    Martikainen MH; Gardberg M; Kohonen Ia; Lähdesmäki J
    Am J Phys Med Rehabil; 2013 Nov; 92(11):1031-4. PubMed ID: 23370588
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias.
    Glueck CJ; Oakes N; Speirs J; Tracy T; Lang J
    Am J Cardiol; 1992 Jul; 70(1):1-9. PubMed ID: 1615846
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Carcinogenicity of lipid-lowering drugs.
    Illingworth R
    JAMA; 1996 May; 275(19):1479-80; author reply 1481-2. PubMed ID: 8622216
    [No Abstract]   [Full Text] [Related]  

  • 57. HMG CoA reductase inhibitors. Current clinical experience.
    Walker JF
    Drugs; 1988; 36 Suppl 3():83-6. PubMed ID: 3076126
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.
    Smith PF; Eydelloth RS; Grossman SJ; Stubbs RJ; Schwartz MS; Germershausen JI; Vyas KP; Kari PH; MacDonald JS
    J Pharmacol Exp Ther; 1991 Jun; 257(3):1225-35. PubMed ID: 1904494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients.
    Martin JE; Cavanaugh TM; Trumbull L; Bass M; Weber F; Aranda-Michel J; Hanaway M; Rudich S
    Clin Transplant; 2008; 22(1):113-9. PubMed ID: 18217912
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia.
    Strauss WE; Lapsley D; Gaziano JM
    Am Heart J; 1999 Mar; 137(3):458-62. PubMed ID: 10047626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.